Navigation Links
Despite Managed Care Obstacles, Interest and Anticipated Use of Centocor Ortho-Biotech's New Psoriasis Agent Stelara (ustekinumab) is High
Date:11/25/2009

EXTON, Pa., Nov. 25 /PRNewswire/ -- BioTrends Research Group, Inc. released Wave 1 of its LaunchTrends(TM): Stelara report, the first in a multi-phase syndicated market research project tracking the launch of Centocor Ortho-Biotech's Stelara, from product launch through the first six months of availability. Each wave of the report provides quantitative information from 75 unique Dermatologists and qualitative information from a subset of 20. The reports assess trial and use of Stelara, obstacles to use, typical patient types, product perceptions, promotional efforts/messages, and satisfaction with the product relative to other approved psoriasis agents.

Virtually all Dermatologists are aware of Stelara and interest in the product is high. Dermatologists view the required health care professional administration and the quarterly maintenance doing option as an advantage compared to other available biologic agents. On the downside, Dermatologists express concerns regarding the difficulty in obtaining managed care approval which has caused delays in the fulfillment of prescriptions for Stelara to date. Stelara uptake may also be somewhat blunted by the shadow of this year's withdrawal of Genentech's Raptiva related to serious adverse events. According to one respondent, "It kind of shell shocked us a little bit and we're always a bit leery about new agents."

Despite these concerns, there is strong interest in Stelara among Dermatologists. Nearly one-third of those surveyed have already prescribed the drug during the first month following launch. Among those who have yet to prescribe, 32% anticipate a product trial in the next three months. Considering the dominant market share position of Enbrel, it is not surprising that Stelara uptake is projected to have the greatest impact on Enbrel use.

The next wave of research will be conducted in January 2010 at three months post launch.

About BioTrends Research Group, Inc.

BioTrends Research Group, Inc. (www.bio-trends.com) provides syndicated and custom market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets. For information on BioTrends publications and research capabilities, please contact us at (610) 363-3872 or www.bio-trends.com.

All company, brand, or product names contained in this document may be trademarks of their respective holders.


Media Contact:
Jennifer Robinson
610-363-3872

SOURCE BioTrends Research Group, Inc.


'/>"/>
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Central and Eastern European Healthcare Markets Hold Strong Potential for Growth Despite the Economic Slowdown, Says Frost & Sullivan
2. Lifesciences IT Spending to Experience Mature Growth Rates Despite Economic Slowdown, Declares Frost & Sullivan
3. $500 Billion Health Care Spend Boosts BRIC Countries Diagnostic Imaging Sales Despite Global Recession, According to Millennium Research Group
4. Despite Recessionary Pressures, Patient and Surgeon Demand Will Drive the Joint Arthroplasty and Fixation Bone Cement Market by 7% Annually Through 2013
5. Plasma Products Safe Despite Swine Influenza Outbreak, Assures International Biopharmaceutical Company Octapharma
6. R&D Spending by U.S. Biopharmaceutical Companies Reaches Record Levels in 2008 Despite Economic Challenges
7. New International Study Shows Women With Symptomatic Fibroids Delaying Treatment Despite Substantial Burden on Quality of Life
8. Despite Advances in the Accuracy of CT Colonography in Detecting Polyps, Digestive Health Experts Urge Patients to Consider Risks and Realities
9. Intermezzo(R) 3.5 mg Achieves Greater Early Bioavailability Than Ambien(R) 10 mg Despite 65% Lower Dose
10. Study Finds PCI Safe, Effective Despite Off-Site Cardiac Surgery
11. Organ Donor Shortage Remains Obstacle for Would-Be Transplant Patients Despite Better Medicine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... YORK and GENEVA , ... announced on World Tuberculosis Day revitalizes efforts to develop ... On World Tuberculosis Day, TB Alliance and ... for the clinical development of sutezolid, an antibiotic drug ... sublicense pertains to the development of sutezolid in combination ...
(Date:3/23/2017)... MOBILE, Ala. , March 23, 2017 Mosaic Life Care, based in ... automate the patient registration process across its network of 58 clinics, located in 22 ... constantly seeking new and innovative ways to improve the delivery of health care to ... Continue Reading ... Mosaic Life Care St. Joseph ...
(Date:3/23/2017)... 2017  Transportation Insight, a multi-modal lead logistics solutions ... management firm with expertise serving clients in the food ... Zaffarano was named a 2017 Food Logistics ... the only publication exclusively dedicated to covering the movement ... "Rick has brought to Transportation Insight a wealth ...
Breaking Medicine Technology:
(Date:3/24/2017)... (PRWEB) , ... March 24, 2017 , ... The ... Quest Awards . The annual awards, now in their 12th year, are among ... selects the winners. , In 2016, the awards were retooled to recognize achievements in ...
(Date:3/24/2017)... ... March 24, 2017 , ... Mlynarek Insurance Agencies, a Detroit ... business owners across eastern Michigan, is connecting with the Oxford/Orion FISH Food Pantry ... , The Oxford/Orion FISH Food Pantry works to ensure homeless, hungry, and underprivileged ...
(Date:3/24/2017)... ... March 24, 2017 , ... Northridge dentists, Dr. ... for sleep apnea and TMJ at their office. TMJ, or temporomandibular joint disorder, ... obstructive type, is increasingly being treated at dental offices with newly developed procedures ...
(Date:3/24/2017)... ... March 24, 2017 , ... Gastro Health (“GH”) ( ... patients for colonoscopy at the HyGIeaCare® Center that is to be located adjacent ... , The HyGIeaCare® Prep, cleared by the U.S. Food and Drug Administration ...
(Date:3/24/2017)... ... March 24, 2017 , ... “End Time GPS”: a dauntless and ... “End Time GPS” is the creation of published author, Wesley Gerboth, a World ... military munitions and space-vehicle projects. Now, at age ninety-one, he shares the Wisdom God ...
Breaking Medicine News(10 mins):